AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The devices are generally used in minimally invasive, image-guided procedures. AngioDynamics product offerings fall within three Global Business Units, namely Oncology/Surgery, Endovascular Therapies and Vascular Access. Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products and Venous Insufficiency. The Thrombus Management portfolio includes the proprietary AngioVac venous drainage cannula and circuit as well as catheter directed thrombolytic devices. Vascular Access arm offers advanced imaging equipment to guide the placement of catheters that primarily deliver short-term drug therapies. IGVA procedures include the placement of Peripherally Inserted Central Catheters lines, implantable ports and central venous catheters. Oncology/Surgery division includes Microwave Ablation, Radiofrequency Ablation and NanoKnife product lines....
+See More2018-04-07 09:36:00 Saturday ET

Facebook CEO Mark Zuckerberg testifies in Congress to rise up to the challenge of public outrage in response to the Cambridge Analytica data debacle and use
2019-07-23 09:22:00 Tuesday ET

Harvard economic platform researcher Dipayan Ghosh proposes some alternative solutions to breaking up tech titans such as Facebook, Google, Apple, and Amazo
2019-07-15 16:37:00 Monday ET

President of US-China Business Council Craig Allen states that a trade deal should be within reach if Trump and Xi show courage at G20. A landmark trade agr
2018-09-07 07:33:00 Friday ET

The Economist re-evaluates the realistic scenario that the world has learned few lessons of the global financial crisis from 2008 to 2009 over the past deca
2018-03-03 11:37:00 Saturday ET

President Xi seeks Chinese congressional approval and constitutional amendment for abolishing his term limits of strongman rule with more favorable trade de
2018-05-13 08:33:00 Sunday ET

Incoming New York Fed President John Williams suggests that it is about time to end forward guidance in order to stop holding the financial market's han